U.S. President Donald Trump announced a 100 percent tariff on imports of branded or patented pharmaceutical drugs, set to take effect on October 1. The measure, confirmed in a post on Trump’s Truth Social account, will apply to drugs manufactured outside the United States unless the manufacturer has already broken ground or started construction on a U.S. production facility. The announcement marks one of the most sweeping trade policy shifts in the pharmaceutical sector by a U.S. administration.
The US tariff will also extend to a range of other consumer goods, including a 50 percent duty on imported kitchen cabinets and vanities, a 30 percent tariff on upholstered furniture, and a 25 percent tariff on heavy trucks. Trump stated that the tariff is designed to increase domestic manufacturing in critical sectors. Exemptions will apply to companies that are actively investing in U.S.-based pharmaceutical production, provided they can show that construction has already begun. Markets reacted immediately. Shares in European and Asian pharmaceutical companies fell following the announcement, with some of the steepest declines seen in Switzerland, Germany, and Ireland, where large drug manufacturers operate export-driven facilities.
In India, where a significant share of the global generic drug supply is produced, stock prices in the pharmaceutical sector also declined. Industry analysts and trade groups warned that the new policy could drive up prescription drug prices for U.S. consumers. Under a 100 percent tariff, affected medications could see their costs double at the border, placing additional pressure on patients, insurers, and federal healthcare programs. The Pharmaceutical Research and Manufacturers of America (PhRMA) has cautioned that tariffs of this magnitude may disrupt supply chains and divert resources from research, development, and innovation.
Global pharmaceutical supply chains face uncertainty
In response to the upcoming tariff, AstraZeneca announced it will reduce U.S. retail prices for select drugs. The company said it will offer its diabetes medication Farxiga at $182 and asthma treatment Airsupra at $249 through direct-to-consumer channels beginning October 1. These prices represent discounts of 70 percent and 50 percent, respectively. The company also confirmed that the same rates would apply to Medicare and Medicaid beneficiaries starting January 2026. AstraZeneca said it plans to invest $50 billion in U.S. manufacturing by 2030, including a new production site in Virginia.
Stock markets react to pharmaceutical trade tensions
The Indian government is reviewing the impact of the tariffs on its pharmaceutical exports. While most Indian exports to the U.S. consist of generic medications, which are not currently included in the scope of the tariffs, authorities are seeking clarity on whether branded generics may be affected. Several ministries, including the Ministry of External Affairs, are actively monitoring the situation. In Europe, officials expressed concern that the new tariffs could breach existing trade agreements. The European Union previously reached a preliminary understanding with U.S. trade officials to cap pharmaceutical tariffs at 15 percent.
Ireland, home to a significant portion of the EU’s pharmaceutical production, has requested urgent clarification from the U.S. regarding the scope and implementation of the tariff. The new tariffs add to a series of protectionist measures introduced during Trump’s second term, which have significantly increased the average U.S. tariff rate across key industries. Economists have warned that further increases in consumer prices could follow, particularly in sectors where domestic alternatives are limited or where imports represent a major share of market supply. – By Content Syndication Services.